Dianthus Therapeutics, Inc. /DE/ (DNTH) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$82.37
-0.1% on the day
+137.0% over 12 months
52-week range $32.92 – $115.96
Share price and insider trades
DNTH closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$71.2M
Insiders buying0
Insiders selling8
Dianthus Therapeutics, Inc. /DE/ insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $71.2M of DNTH stock on the open market.
Get emailed when insiders cluster-buy stocks like DNTH
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
DNTH insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $29.3M | 33 |
| Q2 2026 | — | 0 | $5.6M | 7 |
| Q1 2026 | — | 0 | $28.0M | 21 |
| Q4 2025 | — | 0 | $8.3M | 5 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Dianthus Therapeutics, Inc. /DE/ insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $71.2M. 66 of 66 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 18SEC | Edward CarrChief Accounting Officer | Sell Plan | 7,92812,072 held (−40%) | $100.43 | $796K | -18.0% | — |
| Sep 18SEC | Edward CarrChief Accounting Officer | Sell Plan | 6,7715,301 held (−56%) | $101.37 | $686K | -18.7% | — |
| Sep 18SEC | Edward CarrChief Accounting Officer | Sell Plan | 3,5011,800 held (−66%) | $102.39 | $358K | -19.6% | — |
| Sep 18SEC | Edward CarrChief Accounting Officer | Sell Plan | 1,100700 held (−61%) | $103.20 | $114K | -20.2% | — |
| Sep 18SEC | Edward CarrChief Accounting Officer | Sell Plan | 700 | $104.39 | $73K | -21.1% | — |
| Sep 3SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 13,3094,000 held (−77%) | $106.74 | $1.4M | -22.8% | — |
| Sep 3SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 7,21517,309 held (−29%) | $106.25 | $767K | -22.5% | — |
| Sep 3SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 2,60024,524 held (−10%) | $105.19 | $273K | -21.7% | — |
| Aug 19SEC | Simon ReadDirector | Sell Plan | 2,778 | $117.55 | $327K | -29.9% | — |
| Aug 11SEC | Adam M VenessGeneral Counsel | Sell Plan | 16,167 | $110.38 | $1.8M | -25.4% | — |
| Aug 11SEC | Adam M VenessGeneral Counsel | Sell Plan | 3,217616 held (−84%) | $110.61 | $356K | -25.5% | — |
| Aug 11SEC | Anne McgeorgeDirector | Sell Plan | 2,8003,500 held (−44%) | $108.38 | $303K | -24.0% | — |
| Aug 11SEC | Anne McgeorgeDirector | Sell Plan | 1,8001,700 held (−51%) | $109.30 | $197K | -24.6% | — |
| Aug 11SEC | Anne McgeorgeDirector | Sell Plan | 1,4506,300 held (−19%) | $107.58 | $156K | -23.4% | — |
| Aug 11SEC | Anne McgeorgeDirector | Sell Plan | 1,000700 held (−59%) | $110.64 | $111K | -25.6% | — |
| Aug 11SEC | Simon ReadDirector | Sell Plan | 8311,139 held (−42%) | $108.95 | $91K | -24.4% | — |
| Aug 11SEC | Simon ReadDirector | Sell Plan | 7371,970 held (−27%) | $108.17 | $80K | -23.9% | — |
| Aug 11SEC | Anne McgeorgeDirector | Sell Plan | 700 | $111.41 | $78K | -26.1% | — |
| Aug 11SEC | Adam M VenessGeneral Counsel | Sell Plan | 616 | $111.18 | $68K | -25.9% | — |
| Aug 11SEC | Simon ReadDirector | Sell Plan | 470397 held (−54%) | $111.05 | $52K | -25.8% | — |
| Aug 11SEC | Simon ReadDirector | Sell Plan | 397 | $111.77 | $44K | -26.3% | — |
| Aug 11SEC | Simon ReadDirector | Sell Plan | 272867 held (−24%) | $109.96 | $30K | -25.1% | — |
| Aug 11SEC | Simon ReadDirector | Sell Plan | 702,707 held (−3%) | $107.11 | $7K | -23.1% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 104,09187,102 held (−54%) | $107.96 | $11.2M | -23.7% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 23,907197,001 held (−11%) | $108.05 | $2.6M | -23.8% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 21,90965,292 held (−25%) | $108.72 | $2.4M | -24.2% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 10,384220,908 held (−4%) | $107.49 | $1.1M | -23.4% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 2,536192,092 held (−1%) | $110.02 | $279K | -25.1% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 2,373194,628 held (−1%) | $109.10 | $259K | -24.5% | — |
| Aug 7SEC | Marino GarciaCEO, President | Sell Plan | 800191,292 held (−0%) | $110.76 | $89K | -25.6% | — |
| Jul 13SEC | Ryan SavitzCFO | Sell Plan | 15,3295,566 held (−73%) | $101.24 | $1.6M | -18.6% | — |
| Jul 13SEC | Ryan SavitzCFO | Sell Plan | 10,35420,895 held (−33%) | $100.22 | $1.0M | -17.8% | — |
| Jul 13SEC | Ryan SavitzCFO | Sell Plan | 5,566 | $101.97 | $568K | -19.2% | — |
| Jun 18SEC | Adam M VenessGeneral Counsel | Sell Plan | 16,77113,229 held (−56%) | $80.34 | $1.3M | +2.5% | — |
| Jun 18SEC | Adam M VenessGeneral Counsel | Sell Plan | 13,229 | $81.38 | $1.1M | +1.2% | — |
| Jun 2SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 16,9438,159 held (−67%) | $90.72 | $1.5M | -9.2% | — |
| Jun 2SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 5,42825,102 held (−18%) | $89.72 | $487K | -8.2% | — |
| Jun 2SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 4,1594,000 held (−51%) | $91.37 | $380K | -9.9% | — |
| May 11SEC | Paula SoteropoulosDirector | Sell Plan | 599 | $85.47 | $51K | -3.6% | — |
| Apr 10SEC | Ryan SavitzCFO | Sell Plan | 8,224 | $89.84 | $739K | -8.3% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 59,80026,701 held (−69%) | $83.90 | $5.0M | -1.8% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 21,82591,152 held (−19%) | $78.86 | $1.7M | +4.5% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 19,4697,232 held (−73%) | $84.57 | $1.6M | -2.6% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 7,232 | $85.54 | $619K | -3.7% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 2,36686,501 held (−3%) | $82.84 | $196K | -0.6% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 1,48589,667 held (−2%) | $80.25 | $119K | +2.6% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 1,390112,977 held (−1%) | $78.33 | $109K | +5.2% | — |
| Apr 1SEC | Ryan SavitzCFO | Sell Plan | 80088,867 held (−1%) | $81.36 | $65K | +1.2% | — |
| Apr 1SEC | Paula SoteropoulosDirector | Sell Plan | 599 | $80.11 | $48K | +2.8% | — |
| Mar 26SEC | Paula SoteropoulosDirector | Sell Plan | 27,594 | $78.05 | $2.2M | +5.5% | — |
| Mar 13SEC | Marino GarciaCEO, President | Sell Plan | 65,51713,896 held (−83%) | $81.74 | $5.4M | +0.8% | — |
| Mar 13SEC | Marino GarciaCEO, President | Sell Plan | 43,50579,413 held (−35%) | $80.69 | $3.5M | +2.1% | — |
| Mar 13SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 33,830 | $81.48 | $2.8M | +1.1% | — |
| Mar 13SEC | Edward CarrChief Accounting Officer | Sell Plan | 23,4654,365 held (−84%) | $81.75 | $1.9M | +0.8% | — |
| Mar 13SEC | Edward CarrChief Accounting Officer | Sell Plan | 15,85227,830 held (−36%) | $80.71 | $1.3M | +2.1% | — |
| Mar 13SEC | Marino GarciaCEO, President | Sell Plan | 12,7961,100 held (−92%) | $82.60 | $1.1M | -0.3% | — |
| Mar 13SEC | Edward CarrChief Accounting Officer | Sell Plan | 3,865500 held (−89%) | $82.66 | $319K | -0.4% | — |
| Mar 13SEC | Marino GarciaCEO, President | Sell Plan | 900 | $85.53 | $77K | -3.7% | — |
| Mar 13SEC | Edward CarrChief Accounting Officer | Sell Plan | 300 | $85.53 | $26K | -3.7% | — |
| Mar 13SEC | Edward CarrChief Accounting Officer | Sell Plan | 200300 held (−40%) | $83.38 | $17K | -1.2% | — |
| Mar 13SEC | Marino GarciaCEO, President | Sell Plan | 200900 held (−18%) | $83.38 | $17K | -1.2% | — |
| Dec 5SEC | Ryan SavitzCFO | Sell Plan | 20,000 | $45.18 | $904K | +82.3% | — |
| Nov 14SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 109,0314,000 held (−96%) | $38.14 | $4.2M | +116.0% | — |
| Nov 14SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 42,76522,576 held (−65%) | $37.04 | $1.6M | +122.4% | — |
| Nov 14SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 26,16665,341 held (−29%) | $35.80 | $937K | +130.1% | — |
| Nov 14SEC | Simrat RandhawaEvp, Head Of R&D | Sell Plan | 18,5764,000 held (−82%) | $37.72 | $701K | +118.4% | — |
Insiders at Dianthus Therapeutics, Inc. /DE/
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Marino GarciaCEO, President | — | $28.0M | Aug 7, 2026 | — |
| Simrat RandhawaEvp, Head Of R&D | — | $15.0M | Sep 3, 2026 | — |
| Ryan SavitzCFO | — | $14.3M | Jul 13, 2026 | — |
| Edward CarrChief Accounting Officer | — | $5.6M | Sep 18, 2026 | — |
| Adam M VenessGeneral Counsel | — | $4.6M | Aug 11, 2026 | — |
| Paula SoteropoulosDirector | — | $2.3M | May 11, 2026 | — |
| Anne McgeorgeDirector | — | $845K | Aug 11, 2026 | — |
| Simon ReadDirector | — | $631K | Aug 19, 2026 | — |
DNTH stock: common questions
Are Dianthus Therapeutics, Inc. /DE/ insiders buying DNTH stock?
In the past 12 months, 0 insiders reported open-market purchases of DNTH worth $0.
Are Dianthus Therapeutics, Inc. /DE/ insiders selling DNTH stock?
8 insiders reported sales worth $71.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is DNTH's 52-week range?
Over the past year DNTH has traded between $32.92 and $115.96. It last closed at $82.37 on Oct 9, 2026.